Skip to content
← Layoff Watch

Artiva Biotherapeutics, Inc.

Number not stated

SEC filingAnnounced

Artiva Biotherapeutics, Inc. discloses a restructuring plan in an SEC filing

Industry
Biotech
Filed with the SEC
October 27, 2026
Share of workforce
94%
Whose workers
Scope not stated
In the report for
October 28, 2026

What happened

Artiva Biotherapeutics, Inc. disclosed a restructuring plan in an SEC filing without stating how many jobs it affects. The filing puts the reduction at about 94% of its workforce.

Sources

  • SEC EDGAR · SEC filing · Oct 27, 2026

    On October 22, 2026, the board of directors of the Company approved the discontinuation of the Company’s development of AlloNK ® (AB-101), its non-genetically modified, allogeneic natural killer (NK) cell therapy candidate, as the Company conducts a process to explore strategic alternatives to maximize stockholder value, which includes a plan to implement a reduction of the Company’s workforce by approximately 94% of the Company’s current employee base (the “Wind Down”).
    Read the source

Earlier at Artiva Biotherapeutics, Inc.

This reports what the source says. It says nothing about any individual's immigration status.